Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

F. Barlesi; A.-M.C. Dingemans; J.C.-H. Yang; S.-H.I. Ou; J.S. Ahn; L. De Petris; B. Hughes; H. Lena; W. Bordogna; S. Golding; P.N. Morcos; B. Balas; A. Zeaiter; D.-W. Kim

Journal ArticleOPEN ACCESS

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

Barlesi F
Dingemans A
Yang J
et al.

Annals of Oncology (2016) 27 vi437

DOI: 10.1093/annonc/mdw383.63

N/ACitations

16Readers

Abstract

Methods: Pts ≥18 yrs, ECOG PS 0–2 with confirmed ALK+ NSCLC (by FDA-approved FISH) previously treated with crizotinib received alectinib 600mg BID until progression, death or withdrawal. Co-primary endpoints were objective response rate (ORR) by Independent Review Committee (IRC) in the response evaluable (RE) population using RECIST v1.1 and in pts who had prior chemo. Secondary endpoints included duration of response (DOR); CNS ORR and DOR; disease control rate (DCR); PFS; OS; and safety (CTC v4.0).

Cite

CITATION STYLE

APA

Barlesi, F., Dingemans, A.-M. C., Yang, J. C.-H., Ou, S.-H. I., Ahn, J. S., De Petris, L., … Kim, D.-W. (2016). Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC). Annals of Oncology, 27, vi437. https://doi.org/10.1093/annonc/mdw383.63

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

Abstract

Cite

Register to see more suggestions